EGIS-8332

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522504

CAS#: 220725-87-1

Description: EGIS-8332 is a potent and selective non-competitive AMPA receptor antagonist. EGIS-8332 inhibits AMPA/kainate ion channels and cell death. EGIS-8332 inhibited AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC(50)=5.1-9.0 microM), in vitro. EGIS-8332 seems suitable for further development for the treatment of epilepsy, ischaemia and stroke based on its efficacy in a variety of experimental disease models, and on its low side effect potential.

Chemical Structure

EGIS-8332

CAS# 220725-87-1

Instruction

Theoretical Analysis

MedKoo Cat#: 522504
Name: EGIS-8332
CAS#: 220725-87-1
Chemical Formula: C20H18N4O3
Exact Mass: 362.14
Molecular Weight: 362.389
Elemental Analysis: C, 66.29; H, 5.01; N, 15.46; O, 13.24

Price and Availability

Size	Price	Availability	Quantity
1g	USD -1
2g	USD -1
5g	USD -1
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: EGIS-8332; EGIS 8332; EGIS8332.

IUPAC/Chemical Name: 7-Acetyl-5-(4-aminophenyl)-8-methyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-8-carbonitrile

InChi Key: CBHCOCUJJQDHSR-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H18N4O3/c1-12(25)24-20(2,10-21)9-14-7-17-18(27-11-26-17)8-16(14)19(23-24)13-3-5-15(22)6-4-13/h3-8H,9,11,22H2,1-2H3

SMILES Code: CC(N1C(C#N)(CC2=CC3=C(C=C2C(C4=CC=C(C=C4)N)=N1)OCO3)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 362.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Kovács AD, Saje A, Wong A, Ramji S, Cooper JD, Pearce DA. Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. Neuropharmacology. 2012 Oct;63(5):769-75. doi: 10.1016/j.neuropharm.2012.05.040. Epub 2012 Jun 6. PubMed PMID: 22683643; PubMed Central PMCID: PMC3408822.

2: Kovács AD, Saje A, Wong A, Szénási G, Kiricsi P, Szabó E, Cooper JD, Pearce DA. Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. Neuropharmacology. 2011 Feb-Mar;60(2-3):405-9. doi: 10.1016/j.neuropharm.2010.10.010. Epub 2010 Oct 29. PubMed PMID: 20971125; PubMed Central PMCID: PMC3174473.

3: Cooper JD. Moving towards therapies for juvenile Batten disease? Exp Neurol. 2008 Jun;211(2):329-31. doi: 10.1016/j.expneurol.2008.02.016. Epub 2008 Mar 4. Review. PubMed PMID: 18400221.

4: Kapus GL, Gacsályi I, Vegh M, Kompagne H, Hegedus E, Leveleki C, Hársing LG, Barkóczy J, Bilkei-Gorzó A, Lévay G. Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues. Psychopharmacology (Berl). 2008 Jun;198(2):231-41. doi: 10.1007/s00213-008-1121-z. Epub 2008 Mar 25. PubMed PMID: 18363046.

5: Kovács AD, Pearce DA. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease. Exp Neurol. 2008 Jan;209(1):288-91. Epub 2007 Oct 25. PubMed PMID: 17963751; PubMed Central PMCID: PMC4418195.

6: Gigler G, Móricz K, Agoston M, Simó A, Albert M, Benedek A, Kapus G, Kertész S, Vegh M, Barkóczy J, Markó B, Szabó G, Matucz E, Gacsályi I, Lévay G, Hársing LG Jr, Szénási G. Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models. Br J Pharmacol. 2007 Sep;152(1):151-60. Epub 2007 Jul 2. PubMed PMID: 17603549; PubMed Central PMCID: PMC1978282.

7: Vegh MG, Kovács AD, Kovács G, Szabó G, Tihanyi K, Hársing LG Jr, Lévay G. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death. Neurochem Int. 2007 Feb;50(3):555-63. Epub 2006 Dec 4. PubMed PMID: 17147974.

8: Matucz E, Móricz K, Gigler G, Benedek A, Barkóczy J, Lévay G, Hársing LG Jr, Szénási G. Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats. Brain Res. 2006 Dec 6;1123(1):60-7. Epub 2006 Oct 24. PubMed PMID: 17064671.

9: Gressens P, Spedding M, Gigler G, Kertesz S, Villa P, Medja F, Williamson T, Kapus G, Levay G, Szenasi G, Barkoczy J, Harsing LG Jr. The effects of AMPA receptor antagonists in models of stroke and neurodegeneration. Eur J Pharmacol. 2005 Sep 5;519(1-2):58-67. PubMed PMID: 16112106.

10: Matucz E, Móricz K, Gigler G, Simó A, Barkóczy J, Lévay G, Hársing LG Jr, Szénási G. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia. Brain Res. 2004 Sep 3;1019(1-2):210-6. PubMed PMID: 15306255.

Your view history